 鲜花( 85)  鸡蛋( 2)
|

楼主 |
发表于 2015-2-28 21:48
|
显示全部楼层
Stock soars after Cold-fX wins crucial approval
$ t/ m" z* A/ g' R# T5 v/ @
* Y/ F: a% l, n4 w8 U; }EDMONTON - CV Technologies Inc. shares rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.
" Y2 [& T2 y6 h; n0 q
1 `8 o6 _* ]0 J* `% z' _BY THE EDMONTON JOURNAL FEBRUARY 16, 20076 f: j% ]1 o1 g/ A
" @% ~- k/ w% g2 o" B5 J& A. D$ D0 ?
: s) m! m% h- \$ q6 X
EDMONTON - CV Technologies Inc. SHARES rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.
a5 U- Z2 A7 O& e! S) G* |% {
" I9 v; { F/ M! V! e6 u2 u' C, B) KThe agency said CV Technologies can continue to market Cold-fX as helping "to reduce the frequency, severity and duration of cold and flu symptoms by boosting the IMMUNE SYSTEM."0 E9 L- a7 @) I" E* w* q1 x
- l5 g2 K$ U9 b+ m, |The APPROVAL follows a review of seven clinical trials and more than 10 years of research about the product.* M0 v; q2 P- U/ N( x
7 d5 t% m4 N7 f0 {- s9 }8 XIt should create even more confidence among consumers and medical professionals that the product works, CEO Jacqueline Shan said Thursday.
+ u5 v, Y9 m# ^- Y6 j3 |! {# W1 ^
. D8 a7 m8 B2 J, G! A" @& k! DIt certainly instilled confidence in the market, as shares closed at $2.90 on THE TORONTO STOCK EXCHANGE, up $1.08 on a volume of 4.6 million. z9 y( }( s' K# S8 F) Y6 T# w
6 q, S4 O. e7 j' y0 |
"As a scientist, it's one of the highlights of my CAREER," Shan said.
0 w5 s4 B2 o% O6 g; H4 K T3 Z8 Z& f% I; ]7 _( k7 g
"This approval is a breakthrough in realizing our vision of being a global leader in developing products for disease prevention."
. d" E6 E: N$ P: y J+ }: J6 j' p2 l$ i9 o' _& T! [
It's Cold-fX's strongest medical recognition to date, said Shan. It means the company can advertise the HEALTH BENEFITS more effectively to consumers and health professionals, she said.
2 u, Y( K" X! C# e$ U& m' @5 @- }5 ]1 m/ T, r
Ginseng-based Cold-fX is already the top-selling cold and flu treatment in Canada, but Shan said there is plenty of room for more growth.
5 O- k. a! p) i
6 d4 U, R& k& ~8 P1 HThe approval will also help raise the product's PROFILE in the lucrative U.S. market, which Cold-fX entered in October. The move came with a new marketing push, using former Oilers superstar Mark Messier as its spokesman.
2 P: L( P8 w/ [ f7 H: g5 P- z4 D+ D8 _: Q
; V z$ Z# F% q. l/ J" Z6 [6 Y
http://www.canada.com/story.html ... 9-be80-f40f1426f662 |
|